Drug Trial Radar · NCT05219500
Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
115
Planned (sponsor's estimate)
Start
Dec 16, 2021
Primary completion
May 30, 2025
Study completion Jul 31, 2026
Sponsor
- Lead sponsor
- Fusion Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The treatment regimen will consist of 4 doses of FPI-2265
Conditions
- Metastatic Castration Resistant Prostate Cancer
Interventions
FPI-2265Drug
Small molecule capable of binding to the domain of PSMA radiolabeled with Ac225
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the effect of FPI-2265 on prostate-specific antigen (PSA) in participants with mCRPC.Time frame: From start of treatment until 12 weeks after the first treatment.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
XCancer Omaha/Urology Cancer Center
Omaha, Nebraska
Excel Diagnostics and Nuclear Oncology Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.